Skip to main content

Advertisement

Table 3 Abnormal renal and liver function and serious adverse events

From: How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose

  R+ ≤ 100 mg (n = 38) R+  101–200 mg (n = 46) R+ > 200 mg (n = 48) P value
Liver and renal function adverse events
 GGT 10 (26.3) 12 (26.1) 8 (16.7) 0.45
 ALP 3 (7.9) 1 (2.2) 4 (8.3) 0.39
 AST 4 (10.5) 3 (6.5) 0 (0) 0.09
 ALT 3 (7.9) 4 (8.7) 8 (16.7) 0.35
 CrCL increase > 20% 6 (15.8) 5 (10.9) 8 (16.7) 0.70
 CrCL decrease > 20% 11 (28.9) 9 (19.6) 14 (29.2) 0.49
Serious adverse events
  R+ ≤ 100 mg (n = 38) R+  101–200 mg (n = 46) R+ > 200 mg (n = 48) Total
Cardiac disorders 1 4 (4) 4 (3) 9
Gastrointestinal disorders 1 2 (2) 3 (3) 6
General disorders   1 2 (2) 3
Hepatobiliary disorders    1 1
Infections and infestations   3 (3) 3 (3) 6
Injury, poisoning and procedural complications 1 1 2 (2) 4
Investigations   1   1
Metabolism and nutrition 1    1
Musculoskeletal   3 (2)   3
Nervous system disorders 3 (2)    3
Psychiatric disorders 1    1
Renal and urinary disorders   2 (2)   2
Respiratory   1   1
Skin    1 1
Total number of events (number of participants (% of participants)) 8 (4 (10.5%)) 18 (8 (17.4%)) 16 (10 (20.8%)) 42
  1. Renal and liver function data are reported as the number of participants with at least one CTCAE adverse event in the 12-month dose escalation phase of the study. Serious adverse events are reported as the number of events (number of participants)
  2. R+ amount of allopurinol (milligrams) above creatinine clearance (CrCl)-based dose, GGT gamma-glutamyl transferase, ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine aminotransferase